Minerva Neurosciences宣布成立科学顾问委员会，旨在加速其核心候选药物Roluperidone的研发进程，并为公司未来的管线项目提供战略指导。此举标志着该公司在强化其神经科学领域研发实力方面迈出了关键一步。
科学顾问委员会的成立将汇聚该领域的顶尖专家，他们的专业知识和洞见有望为Roluperidone的临床开发路径提供重要支持，并帮助规划公司长期的产品线布局。这一举措旨在整合外部智慧，以应对复杂的研发挑战，并把握未来的科学机遇。
通过组建这一高水平的顾问团队，Minerva Neurosciences期望能更有效地推进其治疗方案的开发，最终为患者带来新的希望。公司未来的研发方向也将借此平台得到进一步明确和优化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.